These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

320 related articles for article (PubMed ID: 36822363)

  • 81. Evaluating personalized circulating tumor DNA detection for early-stage lung cancer.
    Huang H; Kai Z; Wang Y; Zhang X; Wang J; Zhang W; Xue Q; Zhang H; Jin H; Meng P; Zhang S; Yang Y; Yang H; Liang W; Zha G; Luo P; Xu Y; Shi W; Ruan Z
    Cancer Med; 2024 May; 13(10):e6817. PubMed ID: 38112031
    [TBL] [Abstract][Full Text] [Related]  

  • 82. Personalized circulating tumor DNA detection to monitor immunotherapy efficacy and predict outcome in locally advanced or metastatic non-small cell lung cancer.
    Cheng L; Gao G; Zhao C; Wang H; Yao C; Yu H; Yao J; Li F; Guo L; Jian Q; Chen X; Li X; Zhou C
    Cancer Med; 2023 Jul; 12(13):14317-14326. PubMed ID: 37184093
    [TBL] [Abstract][Full Text] [Related]  

  • 83. Circulating Tumor DNA as a Marker of Minimal Residual Disease After Radical Resection of Colorectal Liver Metastases.
    Marmorino F; Prisciandaro M; Giordano M; Ortolan E; Crucitta S; Manca P; Antoniotti C; Valenti MM; Danesi R; Conca V; Mazzoli G; Boccaccino A; Carullo M; Martinetti A; Sottotetti E; Masi G; Sposito C; Zaffaroni N; Milione M; Fontanini G; Del Re M; Pietrantonio F; Cremolini C
    JCO Precis Oncol; 2022 Nov; 6():e2200244. PubMed ID: 36356286
    [TBL] [Abstract][Full Text] [Related]  

  • 84. Applications of Liquid Biopsy for Surgical Patients With Cancer: A Review.
    Mahuron KM; Fong Y
    JAMA Surg; 2024 Jan; 159(1):96-103. PubMed ID: 37910091
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Circulating tumor DNA: a promising biomarker in the liquid biopsy of cancer.
    Cheng F; Su L; Qian C
    Oncotarget; 2016 Jul; 7(30):48832-48841. PubMed ID: 27223063
    [TBL] [Abstract][Full Text] [Related]  

  • 86. Circulating Tumor DNA as a Biomarker for Monitoring Patients with Solid Cancers: Comparison with Standard Protein Biomarkers.
    Duffy MJ; Crown J
    Clin Chem; 2022 Nov; 68(11):1381-1390. PubMed ID: 35962648
    [TBL] [Abstract][Full Text] [Related]  

  • 87. [Advances in the application of minimal residual disease in non-metastatic colorectal cancer].
    Cao D; Wang F; Zhang RX; Wei B; He MY; Peng JJ; Chen G
    Zhonghua Wei Chang Wai Ke Za Zhi; 2024 Jul; 27(7):749-755. PubMed ID: 39004992
    [TBL] [Abstract][Full Text] [Related]  

  • 88. Personalized Circulating Tumor DNA Biomarkers Dynamically Predict Treatment Response and Survival In Gynecologic Cancers.
    Pereira E; Camacho-Vanegas O; Anand S; Sebra R; Catalina Camacho S; Garnar-Wortzel L; Nair N; Moshier E; Wooten M; Uzilov A; Chen R; Prasad-Hayes M; Zakashansky K; Beddoe AM; Schadt E; Dottino P; Martignetti JA
    PLoS One; 2015; 10(12):e0145754. PubMed ID: 26717006
    [TBL] [Abstract][Full Text] [Related]  

  • 89. The role of circulating tumor DNA in evaluating minimal residual disease in luminal gastrointestinal malignancies.
    Ueberroth BE; Jones JC; Bekaii-Saab T
    Clin Adv Hematol Oncol; 2022 Jul; 20(7):444-455. PubMed ID: 35802877
    [TBL] [Abstract][Full Text] [Related]  

  • 90. Circulating Tumour DNA and Colorectal Cancer: the Next Revolutionary Biomarker?
    Naidoo M; Piercey O; Tie J
    Curr Oncol Rep; 2021 Nov; 23(12):140. PubMed ID: 34735665
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Early Plasma Circulating Tumor DNA as a Potential Biomarker of Disease Recurrence in Non-metastatic Prostate Cancer.
    Fei X; Du X; Gong Y; Liu J; Fan L; Wang J; Wang Y; Zhu Y; Pan J; Dong B; Xue W
    Cancer Res Treat; 2023 Jul; 55(3):969-977. PubMed ID: 36915250
    [TBL] [Abstract][Full Text] [Related]  

  • 92. BESPOKE study protocol: a multicentre, prospective observational study to evaluate the impact of circulating tumour DNA guided therapy on patients with colorectal cancer.
    Kasi PM; Sawyer S; Guilford J; Munro M; Ellers S; Wulff J; Hook N; Krinshpun S; Koyen Malashevich A; Malhotra M; Rodriguez A; Moshkevich S; Grothey A; Kopetz S; Billings P; Aleshin A
    BMJ Open; 2021 Sep; 11(9):e047831. PubMed ID: 34561256
    [TBL] [Abstract][Full Text] [Related]  

  • 93. Circulating tumor DNA analysis detects micrometastatic disease and predicts recurrence in a patient with colon cancer: A case report.
    Luo J; Zhou B; Zhao L; Yuan J; Zhou J; Shen L; Li F; Qian C
    Medicine (Baltimore); 2023 Jul; 102(28):e34330. PubMed ID: 37443478
    [TBL] [Abstract][Full Text] [Related]  

  • 94. Genotyping of circulating cell-free DNA enables noninvasive tumor detection in myxoid liposarcomas.
    Braig D; Becherer C; Bickert C; Braig M; Claus R; Eisenhardt AE; Heinz J; Scholber J; Herget GW; Bronsert P; Fricke A; Follo M; Stark GB; Bannasch H; Eisenhardt SU
    Int J Cancer; 2019 Aug; 145(4):1148-1161. PubMed ID: 30779112
    [TBL] [Abstract][Full Text] [Related]  

  • 95. Association of ctDNA detection and recurrence assessment in patients with neoadjuvant treatment.
    Zhou J; Mo H; Hu D; Zhao X; Zhou H; Pan J
    Cancer Med; 2023 Oct; 12(19):19794-19806. PubMed ID: 37746916
    [TBL] [Abstract][Full Text] [Related]  

  • 96. Current Perspectives on Circulating Tumor DNA, Precision Medicine, and Personalized Clinical Management of Cancer.
    Oliveira KCS; Ramos IB; Silva JMC; Barra WF; Riggins GJ; Palande V; Pinho CT; Frenkel-Morgenstern M; Santos SEB; Assumpcao PP; Burbano RR; Calcagno DQ
    Mol Cancer Res; 2020 Apr; 18(4):517-528. PubMed ID: 31996469
    [TBL] [Abstract][Full Text] [Related]  

  • 97. Combined Analysis of Disseminated Tumor Cells (DTCs) and Circulating Tumor DNA (ctDNA) in a Patient Suffering from Triple Negative Breast Cancer Revealed Elevated Risk.
    Nel I; Herzog H; Aktas B
    Front Biosci (Landmark Ed); 2022 Jun; 27(7):208. PubMed ID: 35866394
    [TBL] [Abstract][Full Text] [Related]  

  • 98. Clinical implications of circulating tumor DNA in predicting the outcome of diffuse large B cell lymphoma patients receiving first-line therapy.
    Li M; Mi L; Wang C; Wang X; Zhu J; Qi F; Yu H; Ye Y; Wang D; Cao J; Hu D; Yang Q; Zhao D; Ma T; Song Y; Zhu J
    BMC Med; 2022 Oct; 20(1):369. PubMed ID: 36280874
    [TBL] [Abstract][Full Text] [Related]  

  • 99. Perioperative circulating tumor DNA enables the identification of patients with poor prognosis in upper tract urothelial carcinoma.
    Nakano K; Koh Y; Yamamichi G; Yumiba S; Tomiyama E; Matsushita M; Hayashi Y; Wang C; Ishizuya Y; Yamamoto Y; Kato T; Hatano K; Kawashima A; Ujike T; Fujita K; Kiyotani K; Katayama K; Yamaguchi R; Imoto S; Imamura R; Nonomura N; Uemura M
    Cancer Sci; 2022 May; 113(5):1830-1842. PubMed ID: 35293110
    [TBL] [Abstract][Full Text] [Related]  

  • 100. [Research Progress of Circulating Tumor DNA in Non-small Cell Lung Cancer].
    Lei S; Wang Y
    Zhongguo Fei Ai Za Zhi; 2022 Sep; 25(9):665-670. PubMed ID: 36172731
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.